Two Sigma Advisers
ACHL

Two Sigma Advisers’s Achilles Therapeutics ACHL Stock Holding History

Two Sigma Advisers’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,200
Closed -$39K – 2623
2024
Q4 		$39K Buy
34,200
+11,800
+53% +$12.2K ﹤0.01% 2301
2024
Q3 		$22.8K Sell
22,400
-1,100
-5% -$881 ﹤0.01% 2248
2024
Q2 		$19.2K Buy
23,500
+5,600
+31% +$4.92K ﹤0.01% 2403
2024
Q1 		$22.4K Buy
+17,900
New +$19.3K ﹤0.01% 2393

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Two Sigma Advisers's ACHL Position: Q1 2025 in Review

Two Sigma Advisers sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 34,200 shares — an estimated $39K sold.

Two Sigma Advisers first reported a position in ACHL in Q1 2024 and held it in 4 quarters. The position peaked at $39K in Q4 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Two Sigma Advisers reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 34,200 Achilles Therapeutics shares in Q1 2025, an estimated $39K.
  • Two Sigma Advisers first reported a position in Achilles Therapeutics in Q1 2024 and held it in 4 quarters.
  • Two Sigma Advisers's Achilles Therapeutics position peaked at $39K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.